We serve Chemical Name:2,3-Dichloro-1,1,1-trifluoropropane CAS:338-75-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,3-Dichloro-1,1,1-trifluoropropane
CAS.NO:338-75-0
Synonyms:2,3-dichloro-1,1,1-trifluoropropane;MFCD00069089
Molecular Formula:C3H3Cl2F3
Molecular Weight:166.95700
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:76-77°C
Density:1.419g/cm3
Index of Refraction:1.367
PSA:
Exact Mass:165.95600
LogP:2.39490
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2,3-dichloro-1,1,1-trifluoropropane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00069089 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3-dichloro-1,1,1-trifluoropropane Use and application,MFCD00069089 technical grade,usp/ep/jp grade.
Related News: With rising demand and approvals required for new drugs, an external collaboration with CDMOs helps in driving a successful and robust clinical development plan for a new drug molecule. 3-(2-(4-methylpiperazin-1-yl)benzyl)-1-(4-(trifluoromethyl)phenyl)pyrrolidin-2-one manufacturers “In the past few years, the pharmaceutical industry has seen rapid growth driven by the growth of small molecules’ innovations, complex APIs and the increasing need to optimize available resources. (6aS,12aS,14aS)-12a,14a-dimethyl-2,4,4a,4b,5,6,6a,7,12,12a,12b,13,14,14a-tetradecahydropyrazolo[3′,4′:3′,4′]cyclopenta[1′,2′:5,6]naphtho[1,2-g]quinazolin-9-amine suppliers The company will see an immediate $6 billion bump to its topline thanks to Alexion’s C5 inhibitors, used to treat rare diseases like paroxysmal nocturnal hemoglobinuria. (12R)-(2,2,3,3,12-2H5)myristic acid vendor & factory The Lonza team also contains regulatory specialists with experience working with Chinese regulators throughout the drug development and scale-up process. Approximately 250 employees work at Lonza’s Nansha site; this expansion is expected to create around 70 new positions.,“We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab,” Sandrock said. “A better understanding of the facts is good for everyone involved to assure confidence in both the therapy and the process by which it was approved as we prioritize the issues that affect patients.”
